Stem cell transplantation for hemoglobinopathies

Current Opinion in Pediatrics

Volumn 15, Issue 1, 2003, Pages 24-31

  Gaziev, Javid ^a   Lucarelli, Guido ^b  

^a Centro Trapianto Midollo Osseo   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; DEFEROXAMINE; FLUDARABINE; HYDROXYUREA; LYMPHOCYTE ANTIBODY; THIOTEPA;

ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CHIMERA; DRUG TOLERABILITY; ENDOCRINE DISEASE; ERYTHROPOIESIS; GENE THERAPY; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GROWTH DISORDER; HAPLOTYPE; HEART DISEASE; HEMOGLOBINOPATHY; HEPATITIS C; HLA TYPING; HUMAN; INFERTILITY; IRON CHELATION; IRON OVERLOAD; LIVER CIRRHOSIS; LIVER FIBROSIS; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; HEMOGLOBINOPATHIES; HUMANS; INFANT; STEM CELL TRANSPLANTATION;

EID: 0037304503     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200302000-00005     Document Type: Review

References (44)

1. Lucarelli G, Galimberti M, Polchi P, et al.: Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990, 322:417-421. •• The original report of the use of risk classes for transplantation in patients with thalassemia.
2. Lucarelli G, Clift R, Galimberti M, et al.: Marrow transplantation for patients with thalassemia: results in Class 3 patients. Blood 1996, 87:2082-2088.
3. Sodani P, Gaziev D, Erer B, et al.: New preparative regimen for bone marrow transplantation in class 3 young and adult thalassemic patients. Bone Marrow Transplant 2002, 29(suppl 2):S30. • This abstract provides data on 29 class 3 patients who received BMT following a new preparative regimen. Patients had survival and thalassemia-free survival 96% and 90%, respectively. Transplant-related mortality and rejection were low in these patients.
4. Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999, 93:1164-1167.
5. Roberts I. Current status of allogeneic transplantation for haemoglobinopathies [review]. Br J Haematol 1997, 98:1-7.
6. Bensinger WI, Martin PJ, Storer B, et al.: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
7. Yesilipek MA, Hazar V, Kupesiz A, et al.: Peripheral blood stem cell transplantation in children with beta-thalassemia. Bone Marrow Transplant 2001, 28:1037-1040.
8. Champlin R, Schmitz N, Horiwitz MM, et al.: Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000, 95:3702-3709.
9. Rosales F, Peylan-Ramu N, Cividalli G, et al.: The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Bone Marrow Transplant 1999, 23:861-865.
10. Gaziev D, Galimberti M, Lucarelli G, et al.: Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplant. Bone Marrow Transplant 2000, 25:815-821.
11. La Nasa G, Giardini C, Argiolu F, et al.: Unrelated donor marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002, 99:4350-4356. •• This study is the largest published to date on unrelated bone marrow transplantation for β-thalassemia major. The report shows that patients who shared at least one extended haplotype had less acute or chronic GVHD and better survival.
12. Issaragrisil S, Suvatte V, Visudhisakchai S, et al.: Bone marrow and cord blood stem cell transplantation for thalassemia in Thailand. Bone Marrow Transplant 1997, 19(suppl 2):54-56.
13. Gluckman E, Rocha V, Chastang CL: Cord blood hematopoietic stem cells biology and transplantation. Hematology (Am Soc Hematol Educ Program) 1996, 1-14.
14. Locatelli F, Rocha V, Reed W, et al.: Related cord blood transplant in patients with thalassemia and sickle cell disease. Bone Marrow Transplant 2002, 29(suppl 2):S68. • This abstract provides data on related cord blood transplantation for thalassemia major or sickle cell anemia patients. Although all patients are alive, the incidence of graft failure was higher in thalassemia patients, suggesting that the best immunosuppression before and after transplant has to be determined.
15. Lucarelli G, Andreani M, Angelucci E: The cure of thalassemia by bone marrow transplantation. Blood Rev 2002, 16:81-85. • This is a more recent update on bone marrow transplantation for thalassemia from the Pesaro BMT Center.
16. Andreani M, Manna M, Lucarelli G, et al.: Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996, 87:3494-3499.
17. Andreani M, Nesci S, Lucarelli G, et al.: Long-term survival of ex-thalassemic patients with persistent mixed chimerism after marrow transplantation. Bone Marrow Transplant 2000, 25:401-404.
18. Lucarelli G, Angelucci E, Giardini C, et al.: Fate of iron stores in thalassemia after bone marrow transplantation. Lancet 1993, 342:1388-1391.
19. Angelucci E, Brittenham GM, McLaren CE, et al.: Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000, 343:327-331.
20. Angelucci E, Muretto P, Nicolucci A, et al.: Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002, 100:17-21. • This study provides data on the natural history of liver fibrosis in ex-thalassemics and demonstrates that iron overload and hepatitis C virus are independent risk factors for liver fibrosis progression following transplant.
21. Angelucci E, Muretto P, Lucarelli G, et al.: Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Group for Phlebotomy Treatment of Transplanted Thalassemic Patients. Blood 1997, 90:994-998.
22. Mariotti E, Angelucci E, Agostini A, et al.: Evaluation of cardiac status in iron-loaded thalassemia patients following bone marrow transplantation: improvement in cardiac function during reduction in iron burden. Br J Haematol 1998, 103:916-921.
23. Giardini C, Galimberti M, Lucarelli G, et al.: Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassemia. Br J Haematol 1995, 89:868-873.
24. Muretto P, Angelucci E, Lucarelli G: Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002, 136:667-672. • This is the first observation of reversibility of cirrhosis following iron depletion in patients who underwent BMT for thalassemia.
25. Gaziev D, Galimberti M, Giardini C, et al.: Growth in children after bone marrow transplantation for thalassemia. Bone Marrow Transplant 1993, 12(suppl 1):100-101.
26. De Simone M, Verrotti A, Iughetti L, et al.: Final height of thalassemic patients who underwent bone marrow transplantation during childhood. Bone Marrow Transplant 2001, 28:201-205.
27. De Sanctis V, Galimberti M, Lucarelli G, et al.: Growth and development in ex-thalassemic patients. Bone Marrow Transplant 1997, 19(suppl 2):126-127.
28. Gaziev D, Polchi P, Galimberti M, et al.: Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 1997, 63:854-860.
29. Gaziev D, Lucarelli G, Galimberti M, et al.: Malignancies after bone marrow transplantation for thalassemia. Bone Marrow Transplant 1997, 19(suppl 2):142-144.
30. Platt OS, Brambilla DJ, Rosse WF, et al.: Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994, 330:1639-1644.
31. Serjeant GR. Natural history and determinants of clinical severity of sickle cell disease. Curr Opin Hematol 1995, 2:103-108.
32. Jonson FL, Look AT, Gockerman J, et al.: Bone marrow transplantation in a patient with sickle cell anemia. N Engl J Med 1984, 311:780-783.
33. Sullivan KM, Parkman R, Walters MC: Bone marrow transplantation for nonmalignant disease. Hematology (Am Soc Hematol Educ Program) 2000, 319-338.
34. Walters MC, Patience M, Leisenring W, et al.: Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996, 2:100-104.
35. Vermylen C, Cornu G, Ferster A, et al.: Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998, 22:1-6.
36. Giardini C, Galimberti M, Lucarelli G, et al.: Bone marrow transplantation in sickle cell disorders in Pesaro. Bone Marrow Transplant 1997, 19(suppl 2):106-109.
37. Bernaudin F, Souillet G, Vannier JP, et al.: Report of the French experience concerning 26 children transplanted for severe sickle cell disease. Bone Marrow Transplant 1997, 19(suppl 2):112-115.
38. Walters MC, Storb R, Patience M, et al.: Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood 2000, 95:1918-1924.
39. Walters MC, Sullivan KM, Bernaudin F, et al.: Neurologic complications after allogeneic marrow transplantation. Blood 1995, 85:879-884.
40. Amrolia PJ, Vulliamy T, Vassiliou G, et al.: Analysis of chimerism in thalassemic children undergoing stem cell transplantation. Br J Haematol 2001, 114:219-225.
41. Walters MC, Patience M, Leisenring W, et al.: Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001, 7:665-673. • This report is the largest published to date on stable mixed chimerism after conventional myeloablative transplantation for sickle cell anemia. The study shows that the incidence of stable mixed chimerism after BMT for sickle cell disease is 26%, and some patients with HbAA donors had mixed chimerism levels of 11%, 67%, and 74%, whereas the levels of HbS on electrophoresis were 7%, 0%, and 0%, respectively, probably as a result of donor erythroid progenitors and/or erythrocytes advantage over sickle cell counterparts.
42. Woodard P, Cunningham JM: Re: measurement of chimerism after hematopoietic stem cell transplantation [letter]. Biol Blood Marrow Transplant 2002, 8:170.
43. Baker SK, Wagner JE: Novel conditioning regimens and nonmyeloablative stem cell transplants. Curr Opin Pediatr 2002, 1:17-22. • This is a more recent review on novel nonmyeloablative or less intensive conditioning regimens for stem cell transplantation in malignant and nonmalignant hematological diseases.
44. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.